Literature DB >> 5013542

Pituitary craniopharyngioma with tooth formation.

T A Seemayer, J S Blundell, F W Wiglesworth.   

Abstract

Entities:  

Mesh：

Year:  1972        PMID： 5013542     DOI： 10.1002/1097-0142(197202)29:2<423::aid-cncr2820290225>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

Review 1.  Toothy craniopharyngioma: a literature review and case report of craniopharyngioma with extensive odontogenic differentiation and tooth formation.

Authors:  Craig Muller; Narosha Adroos; Zarina Lockhat; Tomas Slavik; Henk Kruger
Journal:  Childs Nerv Syst       Date:  2010-10-05       Impact factor: 1.475

Review 2.  Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma.

Authors:  N Karavitaki; B W Scheithauer; J Watt; O Ansorge; M Moschopoulos; A V Llaguno; J A H Wass
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

3.  Jakob Erdheim (1874-1937): father of hypophyseal-duct tumors (craniopharyngiomas).

Authors:  José M Pascual; María Rosdolsky; Ruth Prieto; Sewan Strauβ; Eduard Winter; Walter Ulrich
Journal:  Virchows Arch       Date:  2015-06-19       Impact factor: 4.064

4.  Infrasellar craniopharyngiomas: case report and review of the literature.

Authors:  H Deutsch; K Kothbauer; M Persky; F J Epstein; G I Jallo
Journal:  Skull Base       Date:  2001-05

5.  Endo-suprasellar teratoma with teeth formation. Case report.

Authors:  A N Konovalov; B L Lichterman; A G Korshunov
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

6.  A rare presentation of craniopharyngioma: delayed puberty.

Authors:  Mehmet Fatih İnci; Fuat Özkan; Selim Bozkurt; Caner Feyzi Demir
Journal:  BMJ Case Rep       Date:  2012-11-28

7.  Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Authors:  John R Apps; Gabriela Carreno; Jose Mario Gonzalez-Meljem; Scott Haston; Romain Guiho; Julie E Cooper; Saba Manshaei; Nital Jani; Annett Hölsken; Benedetta Pettorini; Robert J Beynon; Deborah M Simpson; Helen C Fraser; Ying Hong; Shirleen Hallang; Thomas J Stone; Alex Virasami; Andrew M Donson; David Jones; Kristian Aquilina; Helen Spoudeas; Abhijit R Joshi; Richard Grundy; Lisa C D Storer; Márta Korbonits; David A Hilton; Kyoko Tossell; Selvam Thavaraj; Mark A Ungless; Jesus Gil; Rolf Buslei; Todd Hankinson; Darren Hargrave; Colin Goding; Cynthia L Andoniadou; Paul Brogan; Thomas S Jacques; Hywel J Williams; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2018-03-14       Impact factor: 17.088
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.